Psyence Biomedical (PBM) Total Non-Current Liabilities (2024 - 2025)
Psyence Biomedical (PBM) recorded quarterly Total Non-Current Liabilities of $644700.0 in Q3 2025, up 63.52% quarter-over-quarter from $394270.0 in Q1 2025, and down 80.81% on a YoY basis from $3.4 million in Q3 2024.
Psyence Biomedical (PBM) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Psyence Biomedical's Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $644700.0 for Q3 2025.
- In Q3 2025, Total Non-Current Liabilities fell 80.81% year-over-year to $644700.0; the TTM figure through Sep 2025 stood at $644700.0 (down 80.81% YoY), while the FY2025 annual figure was $394270.0, down 96.48% from the prior year.
- Total Non-Current Liabilities was $644700.0 for Q3 2025 at Psyence Biomedical, up from $394270.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $11.2 million in Q1 2024 to a low of $394270.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 42,980.09 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 64.76 Mn |
| 10 | Regeneron Pharmaceuticals | 66.09 Bn | 57.33 Bn | 3.31 Bn | 7.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 644,700.00 |
| Mar 31, 2025 | 394,270.00 |
| Sep 30, 2024 | 3.36 Mn |
| Mar 31, 2024 | 11.20 Mn |